Seeking Alpha

The sector "has been driven by income investors [and] Q2 earnings look tough in this context,"...

The sector "has been driven by income investors [and] Q2 earnings look tough in this context," Jefferies says, in a note on Big Pharma. Analyst Jeffrey Holford likes Novartis (NVS -0.1%), Sanofi (SNY -1.2%), Roche (RHHBY.OB +0.4%), Abbott (ABT -0.1%), AbbVie (ABBV +1.5%), and Bayer (BAYZF.PK +2.3%), and takes a more cautious approach on Bristol-Myers (BMY -0.8%) and Pfizer (PFE -0.7%).
From other sites
Comments (2)
  • DAG Investments
    , contributor
    Comments (4297) | Send Message
     
    That is nothing but a lazy analyst who doesn't want to do homework on individual companies and doesn't understand that pharma valuations are driven by one thing and one thing only -- pipelines.

     

    According to AARP, Pfizer will do $3 billion Lipitor sales in 2015. That sounds more like a modest slope than the fatal "cliff" the shorts (and lazy analysts) have been claiming since 60% ago.
    http://onforb.es/10McjBp

     

    Pfizer Approves $10 Billion Share-Buyback Plan
    http://bloom.bg/18RUuFO
    12 Jul 2013, 10:03 AM Reply Like
  • STREETRE2
    , contributor
    Comments (195) | Send Message
     
    Not to mention Celgene and Gilead who are the new millineal Pharma with innovative and solid pipelines
    13 Jul 2013, 08:21 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs